The role of vaginal progesterone for preterm birth prevention in women with threatened labor and shortened cervix diagnosed after 24 weeks of pregnancy.
prematurity
preterm delivery
preterm labor
progesterone
progestogen
short cervix
singleton pregnancy
transvaginal ultrasound
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
07
08
2022
received:
09
04
2022
accepted:
05
09
2022
pmc-release:
01
05
2024
medline:
19
4
2023
pubmed:
18
9
2022
entrez:
17
9
2022
Statut:
ppublish
Résumé
To determine whether vaginal progesterone treatment for women with a short cervix, diagnosed after 24 weeks of pregnancy, reduces preterm birth rates. A retrospective cohort study that included women with a singleton pregnancy, threatened preterm labor, and a short cervix measured between 24 Patients who received vaginal progesterone had a lower rate of preterm delivery at less than 37 weeks of pregnancy (18.2% [22/121] versus 28.9% [73/253]; adjusted hazard ratio 0.50; 95% confidence interval 0.28-0.73, P = 0.001). The diagnosis-to-delivery interval was significantly greater in patients who received progesterone than in those who did not-median time to delivery in weeks: 8.2 (interquartile range [IQR] 6.2-9.8) versus 6.6 (4.8-8.8), (P < 0.001). The frequency of neonatal intensive care unit admission was significantly lower in patients who received progesterone than in those who did not (8.3% [10/121] versus 16.2% [41/253], P = 0.04). The administration of vaginal progesterone to patients with an episode of threatened premature labor and a short cervix presenting after 24 weeks of pregnancy was associated with lower rates of premature births.
Identifiants
pubmed: 36115013
doi: 10.1002/ijgo.14465
pmc: PMC10020121
mid: NIHMS1839086
doi:
Substances chimiques
Progesterone
4G7DS2Q64Y
Progestins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-431Subventions
Organisme : NICHD NIH HHS
ID : HHSN275201300006C
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 HD002400
Pays : United States
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2022 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
Références
Obstet Gynecol. 2013 Dec;122(6):1279-87
pubmed: 24201691
Am J Obstet Gynecol. 2016 Sep;215(3):B2-7
pubmed: 27133011
Ultrasound Obstet Gynecol. 2011 Jul;38(1):18-31
pubmed: 21472815
Ultrasound Obstet Gynecol. 2011 Jan;37(1):116-26
pubmed: 20842655
Am J Obstet Gynecol. 2014 Nov;211(5):532.e1-9
pubmed: 24907701
Int J Gynaecol Obstet. 2020 Jul;150(1):1-2
pubmed: 32524597
Lancet. 2008 Jan 19;371(9608):261-9
pubmed: 18207020
Am J Obstet Gynecol. 2018 Feb;218(2):161-180
pubmed: 29157866
Ultrasound Obstet Gynecol. 2015 Mar;45(3):308-12
pubmed: 24817155
J Ultrasound Med. 2002 Mar;21(3):227-32; quiz 234-5
pubmed: 11883533
Am J Obstet Gynecol. 2000 Mar;182(3):636-43
pubmed: 10739521
BJOG. 2003 Apr;110 Suppl 20:8-16
pubmed: 12763105
J Matern Fetal Neonatal Med. 2010 May;23(5):379-82
pubmed: 19895354
Am J Obstet Gynecol MFM. 2020 May;2(2):100097
pubmed: 33345963
Am J Obstet Gynecol. 2020 Jul;223(1):42-65.e2
pubmed: 32027880
J Matern Fetal Neonatal Med. 2016;29(11):1789-94
pubmed: 26135787
Int J Gynaecol Obstet. 2020 Jul;150(1):31-33
pubmed: 32524596
Cochrane Database Syst Rev. 2017 Jun 06;6:CD008991
pubmed: 28586127
N Engl J Med. 1996 Feb 29;334(9):567-72
pubmed: 8569824
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Ultrasound Obstet Gynecol. 2016 Sep;48(3):308-17
pubmed: 27444208
Am J Obstet Gynecol. 2021 Mar;224(3):288.e1-288.e17
pubmed: 32918893